{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T22:30:25Z","timestamp":1721946625027},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Association of Nurses in AIDS care"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1177\/1055329003256922","type":"journal-article","created":{"date-parts":[[2004,4,22]],"date-time":"2004-04-22T01:01:24Z","timestamp":1082595684000},"page":"30-41","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular Considerations in Patients Treated with HIV Protease Inhibitors"],"prefix":"10.1097","volume":"15","author":[{"given":"Joseph P.","family":"Colagreco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1177\/1055329003256922_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00042560-200112150-00006","article-title":"Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection","volume":"28","author":"Ammassari","year":"2001","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"Suppl. 1","key":"10.1177\/1055329003256922_bib2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00126334-200202011-00002","article-title":"Addressing the challenges of adherence","volume":"29","author":"Bartlett","year":"2002","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1177\/1055329003256922_bib3","unstructured":"Bernasconi, E. Carota A., Magenta. L, Pons M., Russotti M., Moccetti, T. (1998, June 28-July 3) Metabolic changes in HIVinfected patients treated with protease inhibitors[abstract 12375]. Paper presented at Bridging the Gap: 12thWorld AIDS Conference, Geneva, Switzerland."},{"key":"10.1177\/1055329003256922_bib4","unstructured":"Boyd, M. Duncombe C., Ruxrungthram. K, Khongphattanayothin M., Hassink E., Srasuebkul P. et a (2002) Indinavir TID vs. indinavir\/ritonavir BID in combination with AZT\/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 76-week follow-up[poster 422-W]. Ninth Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/63.126.3.84\/2002\/Abstract\/13001.htm"},{"key":"10.1177\/1055329003256922_bib5","unstructured":"Cahn, P. Casiro A., Puentes. T, David D., Richter C., Stek M., et al (2001) Continued indinavir (800 mgtid) versus switching to indinavir + ritonavir (800\/100 mg bid) in HIV patients having achieved viral load suppression. A randomized study: The Bid Efficacy and Safety Trial (BEST)[abstract 60]. First International Conference on HIV Pathogenesis and Treatment. Retrieved from http:\/\/www.ias.se\/abstract\/show.asp?abstract_id=60"},{"key":"10.1177\/1055329003256922_bib6","unstructured":"Cahn, P. Pantaleo G., Gatell. J, Squires K., Percival L., Piliero P. (2002, May 5-9) Atazanavir: A once-daily protease inhibitor with a superior lipid profile. Paper presented at the XIVth World Congress of Cardiology, Sydney, Australia."},{"key":"10.1177\/1055329003256922_bib7","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome","volume":"14","author":"Carr","year":"2000","journal-title":"AIDS"},{"key":"10.1177\/1055329003256922_bib8","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIVprotease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1177\/1055329003256922_bib9","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1177\/1055329003256922_bib10","unstructured":"Carr, R. A., Andre A. K., Bertz R. J., Hsu A., Lam W., Chang M. et al (2000, September 17-20) Concomitant administration of ABT-378\/ritonavir (ABT-378\/r) results in a clinically important pharmacokinetic (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA)[abstract 1644]. Paper presented at 40th Interscience Conference on Antimicrobial Agents and Chem apy, Toronto, Ontario, Canada."},{"key":"10.1177\/1055329003256922_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0002-9343(84)90952-5","article-title":"Epidemiology of coronary heart disease: The Framingham study","volume":"76","author":"Castelli","year":"1984","journal-title":"American Journal of Medicine"},{"key":"10.1177\/1055329003256922_bib12","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"Journal of the American Medical Association"},{"key":"10.1177\/1055329003256922_bib13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00002030-200104130-00021","article-title":"Indinavir and systemic hypertension","volume":"15","author":"Cattelan","year":"2001","journal-title":"AIDS"},{"key":"10.1177\/1055329003256922_bib14","unstructured":"Cheminot, N. Gariepy J., Chironi. G, Escaut L., Vittecoq D. Simon, A. (2000) Diagnosis and determinants of subclinical arterial disease in HIV-1-infected patients on HAART[abstract 31]. Seventh Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/www.retroconference.org\/2000\/abstracts\/31.htm"},{"key":"10.1177\/1055329003256922_bib15","first-page":"518","article-title":"Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection","volume":"46","author":"Churchill","year":"1998","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1177\/1055329003256922_bib16","unstructured":"Clumeck, N. Brun S., Sylte. J, Isaacson J., Chen S., Lazzarin A. et al (2001) Kaletra (ABT-378\/r) and efavirenz: One-year safety\/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients[abstract 525]. Eighth Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/retroconference.org\/2001\/abstracts\/abstracts\/abstracts\/525.htm"},{"key":"10.1177\/1055329003256922_bib17","unstructured":"Coplan, P., Nikas A., Saah. A, Nessly M., Doll L., Leavitt R. et al (1999) No association observed between indinavir therapy for HIV\/AIDS and myocardial infarction in 4 clinical trials with 2,825 subjects[abstract 658]. Sixth Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/www.retroconference.org\/99\/abstracts\/658.htm"},{"key":"10.1177\/1055329003256922_bib18","unstructured":"Currier, J., Kendall M., Henry. K, Torriani F., Storey S., Shikuma C. et al (2003, February 10-14) Carotid intimamedia thickness in HIV-infected and uninfected adults: ACTG 5078[abstract 131]. Paper presented at the 26th Session, \u201c Metabolic and Opportunistic Infectious Complications of HIV Disease,\u201d of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA."},{"key":"10.1177\/1055329003256922_bib19","unstructured":"Currier, J. S., Johnson D. L. Dub\u00e9, M., Hodis, H. (2000, January 30-February 4) A pilot study of carotid intima media thickness (IMT) in HIV-infected women treated with protease inhibitors[abstract 32]. Paper presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA."},{"key":"10.1177\/1055329003256922_bib20","unstructured":"Curry, R. Markowitz M., Slater. L, Neubacher D., Robinson P., Cotton, G. (2001) Safety and efficacy of tipranavir, a nonpeptidic protease inhibitor, in multiple PI-failure patients(BI 1182.2). IAS Conference. Retrieved from http:\/\/www.ias.se\/abstract\/show.asp?abstract_id=3"},{"key":"10.1177\/1055329003256922_bib21","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJM199512073332303","article-title":"A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease","volume":"333","author":"Danner","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1177\/1055329003256922_bib22","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/317429","article-title":"Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group","volume":"31","author":"Dub\u00e9","year":"2000","journal-title":"Clinical Infectious Diseases"},{"key":"10.1177\/1055329003256922_bib23","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"10.1177\/1055329003256922_bib24","unstructured":"Fichtenbaum, C. Blasschke T., Rosenkranz. S, Segal Y., Aberg J., Gerber J. et al (2000, July 9-14) Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors[abstract WeORB544]. XIII International AIDS Conference, Durban, South Africa. Abstracts-On-Disk\u2122 [CD-ROM]. Whitehouse Station, NJ: Merck Sharp & Dohme."},{"key":"10.1177\/1055329003256922_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1463-1326.2001.00146.x","article-title":"Antiretroviral therapy, insulin resistance and lipodystrophy","volume":"3","author":"Gan","year":"2001","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1177\/1055329003256922_bib26","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0735-1097(99)00387-3","article-title":"AHA\/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology","volume":"34","author":"Grundy","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1177\/1055329003256922_bib27","unstructured":"Haas D., Zala C., Schrader S., Thiry A., McGovern R., Schnittman S. (2001). Once-daily atazanavir plus saquinavir favorably affects total cholesterol (TC) and fasting triglyceride (TG) profiles in patients failing prior PI therapy (trial AI424-009, week 24)[slide session LB-16]. American Society for Microbiology. Retrieved from http:\/\/www.thebody.com\/confs\/icaac2001\/boyle6.html"},{"key":"10.1177\/1055329003256922_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clinical Infectious Diseases"},{"key":"10.1177\/1055329003256922_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00002030-200101260-00013","article-title":"Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV\/AIDS treatment database","volume":"15","author":"Heath","year":"2001","journal-title":"AIDS"},{"key":"10.1177\/1055329003256922_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00126334-200210010-00012","article-title":"Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy","volume":"31","author":"Heath","year":"2002","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1177\/1055329003256922_bib31","unstructured":"Henry, K., (1998, June 28-July 3) Lipid abnormalities associated with use of protease inhibitors: Prevalence, clinical sequelae and treatment[abstract 12319]. Paper presented at Bridging the Gap: 12th World AIDS Conference, Geneva, Switzerland."},{"key":"10.1177\/1055329003256922_bib32","unstructured":"Hewitt, R. G., Thompson W. M. I., Chu A., Hernandez F., Shelton, M. J. (2001) Indinavir, not nelfinavir, is associated with systemic hypertension when compared to no protease inhibitor therapy[abstract 658]. Eighth Conference on Retroviruses and Opportunistic Infections. Retrieved from www.retroconference.org\/2001\/abstracts\/abstracts\/abstracts\/658.htm"},{"key":"10.1177\/1055329003256922_bib33","unstructured":"Hsu, A., Zolopa A., Shulman N. S., Havlir D., Gallant J., Race, E., (2001) Final analysis of ritonavir (RTV) intensification in indinavir (IDV) recipients with detectable HIV RNA levels[abstract 337]. Eighth Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/retroconference.org\/2001\/abstracts\/abstracts\/abstracts\/337.htm"},{"key":"10.1177\/1055329003256922_bib34","unstructured":"Hsyu, P. H., Lewis R. H., Schultz M., Lillibridge J. H., Kerr, B. M. (2000, September 17-20) Pharmacokinetic interactions between nelfinavir and two HMG-CoA reductase inhibitors simvastatin and atorvastatin[abstract 425]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. Abstract Book. Herndon, VA: ASM Press."},{"key":"10.1177\/1055329003256922_bib35","unstructured":"Juette, A., Salzberger B., Franzen. C, Roemer K., Diehl V. Faetkenheuer, G. (1999) Increased morbidity from severe coronary heart disease in HIV patients receiving protease inhibitors[abstract 656]. Sixth Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/www.retroconference.org\/99\/abstracts\/656.htm"},{"issue":"1, part 2","key":"10.1177\/1055329003256922_bib36","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0895-7061(99)00252-6","article-title":"Risk stratification in hypertension: New insights from the Framingham Study","volume":"13","author":"Kannel","year":"2000","journal-title":"American Journal of Hypertension"},{"key":"10.1177\/1055329003256922_bib37","unstructured":"Keruly, J. C., Mehta S., Chaisson R. E., Moore, R. D. (1998, September 24-27) Incidence of and factors associated with the development of hypercholesterolemia and hyperglycemia in HIV-infected patients using a protease inhibitor[abstract I-95]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Abstract Book. Herndon, VA: ASM Press."},{"key":"10.1177\/1055329003256922_bib38","unstructured":"Kingsley, L. Smit E., Riddler. S, Li R., Chmiel J., Palella B. et al (2001) Prevalence of lipodystrophy and metabolic abnormalities in the multicenter AIDS cohort study (MACS)[abstract 538]. Eighth Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/retroconference.org\/2001\/abstracts\/abstracts\/abstracts\/538.htm"},{"key":"10.1177\/1055329003256922_bib39","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/01.ATV.20.12.2625","article-title":"HIV protease inhibitors stimulate hepatic triglyceride synthesis","volume":"20","author":"Lenhard","year":"2000","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1177\/1055329003256922_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1464-2662.2001.00091.x","article-title":"Long-term efficacy and safety of ritonavir\/indinavir at 400\/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy","volume":"3","author":"Lichterfeld","year":"2002","journal-title":"HIV Medicine"},{"key":"10.1177\/1055329003256922_bib41","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1177\/1055329003256922_bib42","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"10.1177\/1055329003256922_bib43","unstructured":"Mary-Krause, M., Cotte L., Partisani M., Simon A., Costagliola, D. (2001) Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men[abstract 657]. Eighth Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/www.retroconference.org\/2001\/abstracts\/abstracts\/abstracts\/657.htm"},{"key":"10.1177\/1055329003256922_bib44","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/00002030-200108170-00007","article-title":"Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy","volume":"15","author":"Moyle","year":"2001","journal-title":"AIDS"},{"key":"10.1177\/1055329003256922_bib45","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200101050-00002","article-title":"ABT-378\/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results","volume":"15","author":"Murphy","year":"2001","journal-title":"AIDS"},{"key":"10.1177\/1055329003256922_bib46","unstructured":"Murphy, R., Thiry A., Mancini. M, Pokrovsky V., Rozenbaum, W. (2002, July 7-12) Switch to atazanavir fromnelfinavir associated with cholesterol and triglyceride improvement: 12 wk results from BMS AI424-044[abstract LbPeB9013]. AIDS 2002\u2014XIV International AIDS Conference, Barcelona, Spain."},{"key":"10.1177\/1055329003256922_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/003655400750045196","article-title":"Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment","volume":"32","author":"Penzak","year":"2000","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1177\/1055329003256922_bib48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","article-title":"Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors","volume":"100","author":"P\u00e9riard","year":"1999","journal-title":"Circulation"},{"key":"10.1177\/1055329003256922_bib49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/517194","article-title":"Ritonavir, triglycerides, and pancreatitis","volume":"28","author":"Perry","year":"1999","journal-title":"Clinical Infectious Diseases"},{"key":"10.1177\/1055329003256922_bib50","unstructured":"Pollner, J., Aronson N. E., McHugh S., Nielson R., Hawkes, C. (1998, June 29) Significant increases in serum cholesterol are seen among HIV patients taking protease inhibitors[abstract 12269]. Paper presented at Bridging the Gap: 12thWorld AIDS Conference, Geneva, Switzerland."},{"key":"10.1177\/1055329003256922_bib51","unstructured":"Polo, R., Madrigal P., Segarra. P, Sanz J., Galindo M., Pulido F., et al (2000, September 17-20) Prevalence of lipodystrophy and metabolic complications in HIV-infected patients: A crosssectional study[abstract 1281]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada. Abstract Book. Herndon, VA: ASM Press."},{"key":"10.1177\/1055329003256922_bib52","doi-asserted-by":"crossref","unstructured":"Powderly, W. G., (2000, September 19) The strategy of antiretroviral switch studies\u2014a review[abstract 1375]. Paper presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Session 146), Toronto, Ontario, Canada. Abstract Book. Herndon, VA: ASM Press.","DOI":"10.1086\/313950"},{"key":"10.1177\/1055329003256922_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200001070-00006","article-title":"Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects","volume":"14","author":"Purnell","year":"2000","journal-title":"AIDS"},{"key":"10.1177\/1055329003256922_bib54","first-page":"47","article-title":"Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: Summary of selected trials","volume":"10","author":"Saag","year":"2002","journal-title":"Topics in HIV Medicine"},{"key":"10.1177\/1055329003256922_bib55","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1177\/1055329003256922_bib56","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1177\/1055329003256922_bib57","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"10.1177\/1055329003256922_bib58","first-page":"443","article-title":"Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study","volume":"5","author":"Schwenk","year":"2000","journal-title":"European Journal of Medical Research"},{"key":"10.1177\/1055329003256922_bib59","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1177\/1055329003256922_bib60","unstructured":"Sosman, J. M., Klein M. A., Bellehumeur J. L., Aeschlimann S. E., Stein, J. H. (2002) Endothelial dysfunction is associated with the use of human immunodeficiency virus-1 protease inhibitors[abstract 29]. Seventh Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/www.retroconference.org\/2000\/abstracts\/29.htm"},{"key":"10.1177\/1055329003256922_bib61","unstructured":"Squires, K., Gatell J., Piliero. P, Sanne I., Wood R., Schnittman, S. M. (2001) AI424-007: 48-week safety and efficacy results from a phase II study of a once-daily HIV-1 protease inhibitor (PI), BMS-232632[abstract 15]. Eighth Conference on Retroviruses and Opportunistic Infections. Retrieved from http:\/\/www.retroconference.org\/2001\/abstracts\/abstracts\/abstracts\/15.htm"},{"key":"10.1177\/1055329003256922_bib62","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","article-title":"Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction","volume":"104","author":"Stein","year":"2001","journal-title":"Circulation"},{"key":"10.1177\/1055329003256922_bib63","first-page":"938","article-title":"Marked hyperlipidaemia on ritonavir therapy","volume":"11","author":"Sullivan","year":"1997","journal-title":"AIDS"},{"key":"10.1177\/1055329003256922_bib64","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00042560-200003010-00009","article-title":"Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998","volume":"23","author":"Thi\u00e9baut","year":"2000","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1177\/1055329003256922_bib65","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1177\/1055329003256922_bib66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00002018-200022060-00003","article-title":"HMG-CoA reductase inhibitors and myotoxicity","volume":"22","author":"Ucar","year":"2000","journal-title":"Drug Safety"},{"key":"10.1177\/1055329003256922_bib67","doi-asserted-by":"crossref","unstructured":"Vancouwenberghe, C., King J. H., Gordon J., McNulty J., Smith B., Mojica, M. (1998, September 24-27) Clinical investigation of the incidence and severity of elevated cholesterol (CH) and triglycerides (TG) in AIDS patients receiving protease inhibitor (PI) therapy[abstract I-69]. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. Abstract Book. Herndon, VA: ASM Press.","DOI":"10.1111\/j.1939-165X.1998.tb01073.x"},{"key":"10.1177\/1055329003256922_bib68","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"NewEngland Journal of Medicine"}],"container-title":["Journal of the Association of Nurses in AIDS care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1055329005600295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1055329005600295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1177\/1055329003256922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:12:52Z","timestamp":1620979972000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055329005600295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S1055329005600295"],"URL":"https:\/\/doi.org\/10.1177\/1055329003256922","relation":{},"ISSN":["1055-3290"],"issn-type":[{"value":"1055-3290","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}